Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows:
Tuesday, February 15 at 9:00 a.m. ET 13th Annual BIO CEO & Investor Conference Panel Topic: "Rheumatoid Arthritis: the Real Joint Problem" Tuesday, February 15 at 3:30 p.m. ET 13th Annual BIO CEO & Investor Conference Rigel Company Presentation (webcast) Thursday, February 17 at 7:45 a.m. ET Leerink Swann Hot Topics in Therapeutics Roundtable Conference Panel Topic: "Rheumatology"
The company presentation at BIO CEO will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA (partnered with AstraZeneca), and R343, an inhaled syk inhibitor that is in clinical trials for asthma (partnered with Pfizer).
SOURCE Rigel Pharmaceuticals, Inc.
Released February 9, 2011